JPRN-UMIN000009421招募中未知
Efficacy and safety of rituximab for intractable immunogenic neurological disorder in children - rituximab for pediatric neurological disorder
Department of Pediatrics, Kobe Universtiy Graduate School of Medicine0 个研究点目标入组 10 人开始时间: 2012年11月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 18years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The patients 1) are affected for infectious disease, 2) are recieved live vaccine within 4weeks, 3) are suffered from heart, lung, liver and kidney disease, 4) have the allergy for rituximab, 5) are ruled unfit to this study.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitisEUCTR2018-000637-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)106
尚未招募
不适用
A study to compare the effectiveness of two drugs, one given orally (tacrolimus) and another as injection (rituximab) in preventing disease recurrences (relapses) in children with frequent relapses of nephrotic syndrome, a kidney disease characterized by protein losses in the urine.CTRI/2018/11/016342Intas Pharmaceuticals Ltd
已完成
不适用
Efficacy and safety of rituximab for patients with severe rheumatic diseaseChildhood-onset severe rheumatic disease (systemic lupus erhythematosus, dermatomyositis, poly myositis, systemic sclerosis , mixed connective tissue disease, Sjogren's syndrome, anti-phospholipid syndrome)JPRN-UMIN000018376Yokohama City University Hospital Department of Pediatrics20
已完成
不适用
A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndromeRefractory nephrotic syndromeJPRN-UMIN000021143Fujita Health University School of Medicine, Department of Nephrology10
进行中（未招募）
不适用
Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRSTMedDRA version: 8.1Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2006-001000-37-DERoche Pharma AG300